Preclinical Evaluation of a ⁶⁴Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma.

ABSTRACT: Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optimal radionuclides which, depending on their emission properties, allow the combination of diagnosis by molecular imaging and targeted radionuclide therapy (TRT). Copper-64 has suitable decay properties (both β⁺ and β- decays) for PET imaging and potentially for TRT, making it both an imaging and therapy agent. We developed and evaluated a theranostic approach using a copper-64 radiolabelled anti-CD138 antibody, [⁶⁴Cu]Cu-TE1PA-9E7.4 in a MOPC315.BM mouse model of multiple mye

SUBMITTER: Metivier C 

PROVIDER: S-EPMC10385603 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature